Our century is characterized by innovative technologies inculcation that is used in all spheres of life including pedagogies promoting the student’s acquaintance with the modern medical and pharmaceutical technologies. For the improvement of pharmacology teaching quality it is necessary to upgrade the pedagogic technologies to the students of medical and pharmaceutical faultiest. With that purpose the biotechnological drugs are included into the pharmacology program for the students in medical and pharmaceutical facilities. Material and methods. Those drugs are obtained by biological effects by using means of special technological processes like cell engineering, hybrid technology, engineering enzymology, engineering immunology and others. The biotechnological drugs include certain antibiotics, hormone and vitamin drugs, drugs of blood, cytokines, immunomodulators, enzymes, lipids, polysaccharides, and monoclonal antibodies. Biotechnological drugs differ from the drugs of chemical synthesis not only by technology of receipt but also by considerable molecular mass, complexity of structure of the proteins in the space, definite isoforms correlation, instability of molecule and other properties. But the biotechnological drugs have the high value connecting with the complicated technological process. It is impossible to create the analogue of biotechnological product by chemical synthesis. When there is wish to reproduce the biotechnological drug the biosimilar may be obtained. It will be investigated in preclinical experiments (in vitro, in vivo) including pharmacokinetics and then in the clinical traits. In Ukraine the biosimilars exchange is regulated by pharmacovigilance system. In the lectures and the practical lessons the pharmacology of the biotechnological drugs is considered by the topics “Hormonal drugs”, “Vitamine drugs”, “Antibiotics” and during the learning of drugs pharmacology that influence on the systems and organs, antineoplastic agents, immunomodulating agents. Conclusions. Teaching students the peculiarities of biotechnological drugs properties promotes the competent approach to the pharmacology study at medical and pharmaceutical facilities. The competent approach to the structure of the pedagogical process of students of medical and pharmaceutical faculties, aimed at improving professional orientation, meets the needs of the healthcare sector, and will contribute to the modernization of the creative and professional activities of future specialists.

Keywords: biotechnological drugs, biosimilars, monoclonal antibodies, professional training

Full text: PDF (Ukr) 225K

1. Oleksina NO, Volosovets OP, Piatnytskyi YuS. Medychna osvita: vidpovidi na vyklyky suchasnosti. Medychna osvita.2018; 2: 36-4. [Ukrainian]
2. Bulakh IY, Voitenko LP, Antonenko YP. Monitorynh yakosti medychnoi osvity. Mizhnarodnyi dosvid. Medychna osvita. 2018; 3: 5-12. [Ukrainian] https://doi.org/10.11603/me.2414-5998.2018.3.9328
3. Talaieva TV, Doroshuk LV, Kudriavtseva IH. Biotekhnolohichni likarski preparaty ta biosymiliary: shcho neobkhidno znaty klinitsystam pry pryznachenni biosymiliariv. Ukrainskyi revmatolohichnyi zhurnal. 2015; 1: 3-7. [Ukrainian]
4. Shirokova I. Biotehnologii na farmryinke. Remedium. Zhurnal o rossiyskom ryinke lekarstv i meditsinskoy tehnike. 2012; 9: 8-25. [Russian]
5. Nesterchuk MM, Baula OP, Hamazin YuO, Doroshuk LV, Matvyeyeva OV. Features of biological / biotechnological products and biosimilars: metod rekomendatsiyi. Kyiv: MOZ Ukrayiny, Derzhavnyy ekspertnyy tsentr; 2013. 38 p.
6. Sylvester K, Rocchio M, Beik N, Fanikos J. Biosimilars: an emerging category of biologic drugs for emergency medicine practitioners. Current Emergency and Hospital Medicine Reports.2013; 1(4): 226-35. https://doi.org/10.1007/s40138-013-0023-5
7. Calvo B. Zuñiga L. EU’s new pharmacovigilance legislation: considerations for biosimilars. Drug safety. 2014; 37(1): 9-18. https://www.ncbi.nlm.nih.gov/pubmed/24190573. https://doi.org/10.1007/s40264-013-0121-z
8. Camacho, LH, Frost CP, Abella E, Morrow PK, Whittaker S. Biosimilars 101: considerations for US oncologists in clinical practice. Cancer Medicine. 2014; 3(4): 889-99. https://www.ncbi.nlm.nih.gov/pubmed/24810680. https://www.ncbi.nlm.nih.gov/pmc/articles/4303156. https://doi.org/10.1002/cam4.258
9. Moorkens E, Meuwissen N, Huys I, Declerck P, Vulto AG, Simoens S. The market of biopharmaceutical medicines: a snapshot of a diverse industrial landscape. Frontiers in pharmacology. 2017; 8: 314. https://www.ncbi.nlm.nih.gov/pubmed/28642701. https://www.ncbi.nlm.nih.gov/pmc/articles/5462923. https://doi.org/10.3389/fphar.2017.00314
10. Eltsova EA, Ramenskaya GV, Smolyarchuk EA, Bushmanova AV. Biosimilyaryi-preparatyi buduschego. Farmakokinetika i farmakodinamika. 2015; 1: 12-5 [Russian]
11. Bezdetko NV. Biosimilyaryi analogov insulina: chto neobhodimo znat klinitsistu. Ukrayinskiy medichniy chasopis. 2016; 1(111): 35-41. [Russian]
12. Golovach IYu. Pytannia bezpeky biosymiliariv analohiv insuliniv: fakty ta poboiuvannia. Endokrynologia. 2017; 22(2): 139-45. [Ukrainian]
13. Walsh G. Biopharmaceutical benchmarks 2018. Nat Biotechnol. 2018; 36: 1136-45. https://www.ncbi.nlm.nih.gov/pubmed/30520869. https://doi.org/10.1038/nbt.4305
14. Rader RA. FDA biopharmaceutical product approvals and trends in 2012. BioProcess Int. 2013; 11.3: 18-27.
15. Ramana K, Xavier J, Sharma R. Recent trends in pharmaceutical biotechnology. Pharm Biotechnol Curr Res. 2017; 1: 1-10.
16. Declerck P, Simoens S. A European perspective on the market accessibility of biosimilars. Biosimilars. 2012; 2: 33-40. https://doi.org/10.2147/BS.S33524
17. Reichert JM. Trends in US approvals: new biopharmaceuticals and vaccines. Trends in biotechnology. 2006; 24.7: 293-8. https://www.ncbi.nlm.nih.gov/pubmed/16759723. https://doi.org/10.1016/j.tibtech.2006.05.003
18. Gorchakova NA, Savchenko NV, Shumeyko EV, Shumeyko NV. Preparatyi monoklonalnyih antitel v meditsinskoy praktike: spektr primeneniya. Farmakologiya i farmakoterapiya: itogi i perspektivyi: monografiya. Novosibirsk: Izd-vo Sibak; 2014. p. 13-20. [Russian]